Tony de Fougerolles

Summary

Affiliation: Alnylam Pharmaceuticals
Country: USA

Publications

  1. ncbi Interfering with disease: a progress report on siRNA-based therapeutics
    Antonin de Fougerolles
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nat Rev Drug Discov 6:443-53. 2007
  2. ncbi Delivery vehicles for small interfering RNA in vivo
    Antonin R de Fougerolles
    Alnylam Pharmaceuticals, Cambridge, MA 02142, USA
    Hum Gene Ther 19:125-32. 2008
  3. ncbi A status report on RNAi therapeutics
    Akshay K Vaishnaw
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Silence 1:14. 2010
  4. ncbi siRNA and the lung: research tool or therapeutic drug?
    Antonin de Fougerolles
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, United States
    Curr Opin Pharmacol 8:280-5. 2008
  5. ncbi Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death
    Vineet Bhandari
    Division of Perinatal Medicine, Yale University School of Medicine, Department of Pediatrics, 333 Cedar Street, New Haven, Connecticut 06520-8064, USA
    Nat Med 12:1286-93. 2006

Collaborators

  • Hans Peter Vornlocher
  • J Lieberman
  • Antonin de Fougerolles
  • Antonin R de Fougerolles
  • Akshay K Vaishnaw
  • John Maraganore
  • Vineet Bhandari
  • Rachel Meyers
  • Jared Gollob
  • Renta Hutabarat
  • Dinah Sah
  • Christina Gamba-Vitalo
  • Tatiana Novobrantseva
  • Robert J Homer
  • Zhou Zhu
  • Rayman Choo-Wing
  • Patty J Lee
  • Lorraine B Ware
  • Chun G Lee
  • Geoffrey L Chupp
  • Michael A Matthay
  • Anke Geick
  • Xucher Zhang
  • Jonathan H Nedrelow
  • Jack A Elias

Detail Information

Publications5

  1. ncbi Interfering with disease: a progress report on siRNA-based therapeutics
    Antonin de Fougerolles
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nat Rev Drug Discov 6:443-53. 2007
    ..We conclude by reviewing the latest clinical experience with RNAi therapeutics...
  2. ncbi Delivery vehicles for small interfering RNA in vivo
    Antonin R de Fougerolles
    Alnylam Pharmaceuticals, Cambridge, MA 02142, USA
    Hum Gene Ther 19:125-32. 2008
    ..Lastly, a status report on current clinical trials using siRNA is given...
  3. ncbi A status report on RNAi therapeutics
    Akshay K Vaishnaw
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Silence 1:14. 2010
    ....
  4. ncbi siRNA and the lung: research tool or therapeutic drug?
    Antonin de Fougerolles
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, United States
    Curr Opin Pharmacol 8:280-5. 2008
    ..In this review, we will discuss the progress made in developing RNAi therapeutics for the treatment of respiratory diseases...
  5. ncbi Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death
    Vineet Bhandari
    Division of Perinatal Medicine, Yale University School of Medicine, Department of Pediatrics, 333 Cedar Street, New Haven, Connecticut 06520-8064, USA
    Nat Med 12:1286-93. 2006
    ..Tracheal Ang2 is also increased in neonates that develop bronchopulmonary dysplasia. Ang2 is thus a mediator of epithelial necrosis with an important role in hyperoxic ALI and pulmonary edema...